HSPA1A and female reproductive organ cancer: Currently the only small molecule HSP70 inhibitor in clinical trial as a cancer therapeutic is SHetA2, which is being evaluated in an oral capsule formulation for treatment of advanced or recurrent gynecologic cancers (NCT 04928508).